-+ 0.00%
-+ 0.00%
-+ 0.00%

Oscar Health (OSCR) Tests Its Growth Story After Board Changes And Texas Expansion

Simply Wall St·11/18/2026 01:12:12
Listen to the news

Oscar Health (OSCR) just moved on two fronts that matter for shareholders. Fresh board appointments from tech and healthcare arrived alongside a broader Texas plan lineup, including RetireEase, Hola Oscar, Buena Salud, and new supplemental options.

The latest board refresh and Texas product rollout arrive after a choppy few weeks for Oscar Health, with the share price down 4.8% on the day and 10.9% over the past week, while still showing a 99.3% year to date share price return and a 1-year total shareholder return of 102.9%. This points to strong longer term momentum despite the recent cooling.

Scan how Oscar Health’s AI driven healthcare model compares with other listed insurers and tech powered medical players by reviewing the hand picked 36 healthcare AI stocks in the same space.

The share price has cooled while analyst targets sit higher, creating a clear gap between Oscar Health’s current US$29.84 and the US$37 consensus. How far does fair value stretch within that range?

Most Popular Narrative: 95% Undervalued

On the numbers alone, Oscar Health looks dramatically cheaper than the fair value set out in the most followed narrative, which pegs intrinsic value at $583.34 against the latest $29.84 close. According to J_Tyrader, an investor in the Simply Wall St Community who wrote the narrative, that gap rests on an aggressive DCF view of Oscar Health’s future cash generation.

I ran them through a rigorous two-stage Discounted Cash Flow (DCF) model. I plugged in a conservative 25.0% growth rate for the next decade, letting it fade gently to a 2.5% terminal rate. Even with a strict 9.6% discount rate, I found an intrinsic value of USD $583.34.

At the time, it was going for just USD $26.88.

See why 14 investors see Oscar Health as 95% undervalued.

Result: Fair Value of $583.34 (UNDERVALUED)

Still, the story can crack if Oscar Health delivers weaker cash generation than the narrative assumes, or if sentiment toward high growth insurers reverses sharply.

Find out about the key risks to this Oscar Health narrative.

Next Steps

Plenty of optimism and concern sit side by side in the Oscar Health story, so move quickly, review the data, and weigh the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Oscar Health?

If Oscar Health has sharpened your interest in healthcare and growth stories, you can broaden your watchlist with a few focused sets of potential opportunities.